Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management

NAPERVILLE, Ill., Oct. 18, 2017 /PRNewswire/ -- Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management. Inadequate pain control is a major public health concern in the USA. Dr. Anil Gulati and his colleagues have been working on this technology since 2002, and have conducted extensive studies and demonstrated that endothelin-A receptor antagonists such as PMZ-2123 potentiate analgesic effects of morphine and oxycodone and eliminates tolerance to these drugs. Dr. Gulati who is the inventor remarked that "the development of PMZ-2123 will have major clinical impact in reducing the use of opioids and maintain adequate pain relief." Pharmazz is undertaking to develop PMZ-2123 under this license that will eliminate the need to increase the dose of opioids when used repeatedly in patients. Since PMZ-2123 has the ability to reverse opioid tolerance, patients who have already developed tolerance to opioids can also be treated with PMZ-2123 and achieve adequate pain relief with lower doses of opioids. Intravenous administration of PMZ-2123 in animal model of opioid tolerance completely restored that analgesic effect of morphine and oxycodone. Successful development of PMZ-2123 will complement the national and state efforts to reduce the risk of abuse, misuse, addiction, overdose, and deaths due to prescription opioid analgesics.

Chronic pain affects over 100 million Americans annually, and inadequate control of pain costs the nation an estimated $560-$635 billion annually in direct care and loss of productivity. Inadequate analgesia can increase the body's stress response and suppress cellular immunity and increase chances of postsurgical infections. Acute postoperative pain can manifest into chronic persistent postsurgical pain if not managed adequately. The annual costs of medications prescribed for nonmalignant chronic pain totaled $17.8 billion annually in 2010. Of these, opioids were among the top categories, at an annual cost of $3.6 billion.

About Pharmazz, Inc. 
Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.  

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact
Pharmazz, Inc.  
Shruti Gulati
630-780-6087
[email protected] 

SOURCE Pharmazz, Inc.